Ethicon touts progress on multi-year bariatric surgery evidence initiative

Johnson & Johnson (NYSE:JNJ) subsidiary Ethicon said today it has made major progress in its “Project Game Changer” initiative which looks to close evidence gaps and reduce clinical and economic barriers for access to surgical treatments for treating obesity and related diseases.

With the Game Changer Initiative, the company said it is focusing its research and evidence generation efforts on the safety and effectiveness of bariatric surgery on reducing obesity and obesity-related diseases, including type 2 diabetes, heart diseases and orthopedic conditions.

“A wide range of evidence guides innovation, adoption of procedures and everyday treatment decisions. We are committed to working with the bariatric community to advance the specialty and expand access for the benefit of patients everywhere. Significant progress has been made, but much work is left to do,” J&J innovation metabolic therapeutic area lead Dr. Elliott Fegelman said in a press release.

Ethicon said that several studies so far have been published as part of the initiative, with more underway.

“Groundbreaking clinical and economic studies, major treatment guidelines and real world evidence have contributed to the transformation of bariatric surgery from what was once considered by some to be either cosmetic or high risk to an effective lifesaving operation whose benefits go far beyond weight loss,” Ethicon company group chair Michael del Prado said in a prepared statement.

Earlier this month, Ethicon said it launched the ProxiSure laparoscopic suturing device.

The post Ethicon touts progress on multi-year bariatric surgery evidence initiative appeared first on MassDevice.

from MassDevice http://ift.tt/2wTVmwu